GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Float Percentage Of Total Shares Outstanding

Cardiff Oncology (STU:XE7C) Float Percentage Of Total Shares Outstanding : 97.17% (As of May. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cardiff Oncology Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiff Oncology's float shares is 43.45 Mil. Cardiff Oncology's total shares outstanding is 44.72 Mil. Cardiff Oncology's float percentage of total shares outstanding is 97.17%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiff Oncology's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiff Oncology's Institutional Ownership is 8.73%.

Cardiff Oncology Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Cardiff Oncology's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=43.45/44.72
=97.17%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology (STU:XE7C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (STU:XE7C) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
SABS IMUX SRNEQ OCUP KZR ANEB HRGN AVRO NKGN INAB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
CRDF:USA XE7C:Germany
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Website
https://www.cardiffoncology.com
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Cardiff Oncology (STU:XE7C) Headlines

No Headlines